GSK offloads registrational liver disease therapy to Alfasigma: Deals Report

Weeks ahead of the regulatory goal date for linerixibat, GSK has granted Italy’s Alfasigma global rights to the liver disease therapy for $300 million up front.

The deal’s price could swell by another $100 million this month upon fulfillment of a key milestone: FDA approval of the treatment for primary biliary cholangitis, which could occur by its PDUFA date of March 24. In the Phase III GLISTEN study, the ileal bile acid transport inhibitor led to a significant reduction in cholestatic pruritus, the itching associated with PBC. GSK plc (LSE:GSK; NYSE:GSK) said the therapy is also under review in the EU, U.K., China and Canada...